Literature DB >> 19356802

Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis.

Manpreet Kaur1, Hema Chug, Harpreet Singh, Subhash Chandra, Manish Mishra, Meenakshi Sharma, Rakesh Bhatnagar.   

Abstract

Bacillus anthracis is the etiological agent of anthrax. Protective antigen (PA) has been established as the key protective immunogen and is the major component of anthrax vaccine. Prior studies have indicated that C-terminus host cell receptor binding region contains dominant protective epitopes of PA. In the present study, we focused our attention on determining B-cell epitopes from this region, which could be employed as a vaccine. Using B-cell epitope prediction systems, three regions were identified; ID-I: 604-622, ID-II: 626-676 and ID-III: 707-723 aa residues. These epitopes elicited potent B-cell response in BALB/c mice. ID-II in particular was found to be highly immunogenic in terms of IgG antibody titre, with a predominantly IgG1/IgG2a subclass distribution indicating Th2 bias and high affinity/avidity index. Effective cellular immunity was additionally generated which also signified its Th2 bias. Further, ID-II induced high level of lethal toxin neutralizing antibodies and robust protective immunity (66%) against in vivo lethal toxin challenge. Thus, ID-II can be classified as an immunodominant B-cell epitope and may prove significant in the development of an effective immunoprophylactic strategy against anthrax.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356802     DOI: 10.1016/j.molimm.2008.12.031

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

3.  Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans.

Authors:  Xu'ai Lin; Jinfang Zhao; Jing Qian; Yafei Mao; Jianping Pan; Liwei Li; Huiqin Peng; Yihui Luo; Jie Yan
Journal:  Clin Vaccine Immunol       Date:  2010-03-17

4.  Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge.

Authors:  Kanchan Sinha; Rakesh Bhatnagar
Journal:  Med Microbiol Immunol       Date:  2012-12-21       Impact factor: 3.402

5.  Th2-biased immune response and agglutinating antibodies generation by a chimeric protein comprising OmpC epitope (323-336) of Aeromonas hydrophila and LTB.

Authors:  Mahima Sharma; Pujarini Dash; Pramod K Sahoo; Aparna Dixit
Journal:  Immunol Res       Date:  2018-02       Impact factor: 2.829

6.  MHC class II and non-MHC class II genes differentially influence humoral immunity to Bacillus anthracis lethal factor and protective antigen.

Authors:  Lori Garman; Eric K Dumas; Sridevi Kurella; Jonathan J Hunt; Sherry R Crowe; Melissa L Nguyen; Philip M Cox; Judith A James; A Darise Farris
Journal:  Toxins (Basel)       Date:  2012-12       Impact factor: 4.546

7.  On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.

Authors:  Salvador Eugenio C Caoili
Journal:  Adv Bioinformatics       Date:  2012-11-14

8.  A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challenge.

Authors:  Manish Manish; Amit Rahi; Manpreet Kaur; Rakesh Bhatnagar; Samer Singh
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

9.  Benchmarking B-cell epitope prediction with quantitative dose-response data on antipeptide antibodies: towards novel pharmaceutical product development.

Authors:  Salvador Eugenio C Caoili
Journal:  Biomed Res Int       Date:  2014-05-11       Impact factor: 3.411

10.  A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis.

Authors:  Saugata Majumder; Shreya Das; Vikas Somani; Shivakiran S Makam; Kingston J Joseph; Rakesh Bhatnagar
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.